Assistant Professor, Division of Hematology and Oncology
To see if Anjlee Mahajan is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
2279 45th Street
Sacramento, CA 95817
3160 Folsom Blvd
Sacramento, CA 95816
I believe it is important to create a trustful and caring relationship with all of my patients. I aim to treat all patients as I would want my own family and friends treated. My goal is to provide you with my own expertise and education to allow you to better make healthcare decisions. I value your trust in me and look forward to partnering to improve your health.
Dr. Mahajan is a board certified hematologist and oncologist. She has a clinical and research interest in thrombosis and hemostasis (bleeding disorders). She has expertise in treatment of venous thromboembolism (including deep vein thrombosis and pulmonary embolism) as well as cancer-associated thrombosis.
Dr. Mahajan's research focuses on using large datasets to explore outcomes in venous thromboembolism, particularly in the area of cancer-associated thrombosis.
Hematology and Oncology
B.S., Biology, UCLA, Los Angeles CA 2004
M.D., Albert Einstein College of Medicine, Bronx NY 2009
Internal Medicine, UC Davis Medical Center, Sacramento CA 2009-2010
Internal Medicine, UC Davis Medical Center, Sacramento CA 2010-2012
Hematology and Oncology, UC San Francisco Medical Center, San Francisco CA 2013-2016
Sacramento Magazine Top Doctor Hematology/Oncology, UC Davis Department of Internal Medicine, 2019, 2020
Honorary participant, American Society of Hematology Medical Educator Institute, 2019
American Society of Hematology (ASH) Ambassador Program, 2018, 2019, 2020, 2021
To view a detailed list of Dr. Mahajan's publications, please click here.
Lee A, Oley F Jr, Lo M, Fong R, McGann M, Saunders I, Block S, Mahajan A, Pon TK. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res. 2021 Dec;208:148-155. doi:10.1016/j.thromres.2021.10.023. Epub 2021 Oct 29. PMID:34798446.
Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022 Jan 11;6(1):307-320. doi:10.1182/bloodadvances.2021005590. PMID:34649273.
Mahajan A, White RH. In cancer-related VTE, DOACs reduce recurrent VTE compared with LMWH; groups do not differ for major bleeding. Ann Intern Med. 2020 Dec 15;173(12):JC62. doi:10.7326/ACPJ202012150-062. PMID:33316186.
Poh C, Brunson A, Keegan T, Wun T, Mahajan A. Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality. TH Open. 2020 Oct 28;4(4):e309-e317. doi:10.1055/s-0040-1718883. PMID:33134806.
Hariharan N, Brunson A, Mahajan A, Keegan THM, Wun T. Bleeding in patients with sickle cell disease: a population-based study. Blood Adv. 2020 Mar 10;4(5):793-802. doi:10.1182/bloodadvances.2019000940. PMID:32108229.
Mahajan A, Brunson A, Keegan THM, Rosenberg A, Wun T. High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. Leuk Lymphoma. 2020 Nov;61(11):2605-2613. doi:10.1080/10428194.2020.1780584. Epub 2020 Jun 23. PMID:32573292.